IMR Press / EJGO / Volume 19 / Issue 5 / pii/1998199

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Report on the antiemetic effectivity of a single 1 mg oral granisetron in moderately emetogenic chemotherapies of gynecological malignancies

Show Less
1 Gynecologic Oncology Department, National Institute of Oncology, Budapest, Hungary
Eur. J. Gynaecol. Oncol. 1998, 19(5), 449–452;
Published: 10 October 1998

Objective: On the basis of the relatively long 9-12 hour plasma-half-life of the highly selective serotonin antagonist granisetron (GRAN) and on observations that emetic episodes are detected mainly IO hours after starting chemotherapy it was supposed that a single I mg oral GRAN (Kytril™, SmithKline Beecham) is enough to prevent the emesis of moderately emetogenic chemothe­rapies. Materials and methods: A total of 45 gynecological cancer patients were treated in 115 chemotherapy cycles with a single 1 mg oral GRAN in a prospective, non-randomized study. Patients stayed in hospital for 24 hours after chemotherapy and emetic episo­des were registered on special charts. Results: A complete response (CR) of 83.4% was found in the 115 cycles. Thirty-seven of the total 45 patients with ovarian cancer had a 84.7% CR in the first 24 hours of chemotherapy. In 29 patients 50 mg/m2 cisplatin was administered with a 79.9% CR. Conclusions: 1 mg oran GRAN is a suitable antiemetic therapy in moderately emetogenic chemotherapies.

Oral granisetron
Chemotherapy-induced emesis
5HT3 antagonist
Back to top